With new Omi­cron da­ta, Ada­gio halts tri­als for vaunt­ed Covid an­ti­body but sees a path ahead

4 years ago
R&D
Coronavirus

Vig­il Neu­ro­science hits Wall Street with two ex-Am­gen TREM2 ag­o­nists

4 years ago
Financing

CRO own­er pleads guilty to ob­struct­ing FDA in­ves­ti­ga­tion in­to fal­si­fied clin­i­cal tri­al da­ta

4 years ago
Outsourcing
FDA+

Three years, a clin­i­cal hold and a death lat­er, Sarep­ta aban­dons part­nered piv­otal-stage gene ther­a­py

4 years ago
Deals
Cell/Gene Tx

Can­cer pow­er­house As­traZeneca rolls the dice on a $75M cash bet on a buzzy up­start in the on­col­o­gy field

4 years ago
R&D

#JPM22: Catal­ent CEO John Chimin­s­ki with John Car­roll — Our pre­dic­tions for the bio­phar­ma in­dus­try in 2022

4 years ago
Manufacturing

#JPM22: 4 top R&D chiefs dis­cuss the key forces re­shap­ing bio­phar­ma

4 years ago
R&D

As Abec­ma sales take off, Bris­tol My­ers and 2sev­en­ty scrap a fol­low-up CAR-T

4 years ago
R&D

Ac­tress Jen­nifer Anis­ton stars in Idor­si­a's de­but cam­paign to raise aware­ness for in­som­nia

4 years ago
Pharma
Marketing

In pur­suit of bet­ter he­parin man­u­fac­tur­ing process, Gink­go teams up with an Ohio-based biotech

4 years ago
Manufacturing

‘Skin­ny la­bels’ on gener­ics can save pa­tients mon­ey, re­search shows, but re­cent court de­ci­sions cloud fu­ture

4 years ago
Pharma

Dai­ichi Sankyo shuts down Plexxikon sub­sidiary to stream­line En­her­tu, ADC de­vel­op­ment

4 years ago
People
R&D

Ex­clu­sive: Bio­gen pres­i­dent fears CMS will fi­nal­ize re­stric­tive cov­er­age de­ci­sion for Aduhelm, preps plans to flood ...

4 years ago
R&D
Pharma

Sanofi joins the al­pha-synu­cle­in band­wag­on, hand­ing Ko­re­an biotech $75M for pre­clin­i­cal bis­pe­cif­ic

4 years ago
Deals

Covid-19 roundup: FDA ad­dress­es risk of ex­ces­sive bleed­ing af­ter J&J vac­cine; No­vavax vac­cine gets OK in South ...

4 years ago
Coronavirus

Reel­ing from FDA re­jec­tion, Be­yond­Spring ax­es 35% of US staffers in hopes of I/O come­back

4 years ago
People
China

How a tiny Swiss lab and two old blood sam­ples cre­at­ed one of the on­ly ef­fec­tive drugs against Omi­cron (and why we ...

4 years ago
Coronavirus
In Focus

'Seeds of change' sprout in­to high­er pro­ject­ed re­turn on in­vest­ments for the bio­phar­ma in­dus­try, ac­cord­ing to ...

4 years ago
Pharma

Wood­cock de­fends FDA's re­sponse to Omi­cron be­fore Sen­ate health com­mit­tee

4 years ago
FDA+
Coronavirus

Pfiz­er lays off hun­dreds of US sales rep as few­er in-per­son meet­ings ex­pect­ed to re­main per­ma­nent

4 years ago
Pharma
Marketing

CMS to re­strict cov­er­age of Bio­gen's con­tro­ver­sial Alzheimer's drug to on­ly clin­i­cal tri­als

4 years ago
Pharma

Mi­cro-in­flu­encers with a ma­jor plat­form: Are they the next big thing in phar­ma mar­ket­ing?

4 years ago
Marketing

Mar­ket­ingRx roundup: Neu­ro­crine amps tar­dive dysk­i­ne­sia cam­paign; FDA study finds an­i­ma­tion has lit­tle ef­fect in DTC ...

4 years ago
Pharma
Marketing

En­do piv­ots from NFL star John El­way to re­al pa­tients in Dupuytren’s con­trac­ture aware­ness ads

4 years ago
Pharma
Marketing
First page Previous page 591592593594595596597 Next page Last page
A service from the Financial Times